Stocktoria
GLOBUS MEDICAL INC GMED
GLOBUS MEDICAL INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.5B | $1.6B | $1.0B | $958.1M | $789.0M | $785.4M | $713.0M | $636.0M | $564.0M |
| Gross profit | — | — | $1.0B | $759.1M | $718.9M | $571.6M | $605.4M | $553.6M | $485.5M | $429.3M |
| R&D expense | $147.2M | $163.8M | $124.0M | $73.0M | $97.3M | $84.5M | $60.1M | $55.5M | $43.7M | $44.5M |
| SG&A expense | $1.2B | $981.4M | $643.8M | $432.1M | $408.1M | $354.8M | $354.8M | $311.6M | $267.8M | $222.2M |
| Operating income | $479.8M | $166.0M | $133.1M | $228.0M | $172.0M | $111.4M | $172.0M | $169.3M | $161.8M | $154.1M |
| Income tax | $67.2M | $17.7M | $42.5M | $52.9M | $31.2M | $23.6M | $34.7M | $32.1M | $62.6M | $52.9M |
| Net income | $537.9M | $103.0M | $122.9M | $190.2M | $149.2M | $102.3M | $155.2M | $156.5M | $107.3M | $104.3M |
| EPS (diluted) | $3.92 | $0.75 | $1.07 | $1.85 | $1.44 | $1.01 | $1.52 | $1.54 | $1.10 | $1.08 |
| Operating cash flow | $753.4M | $520.6M | $243.5M | $178.5M | $276.3M | $198.8M | $172.0M | $181.6M | $159.1M | $147.8M |
| Free cash flow | $588.8M | $405.2M | $165.2M | $104.4M | $219.4M | $135.1M | $101.2M | $121.9M | $107.8M | $106.9M |
| Cash & equivalents | $526.2M | $784.4M | — | — | — | — | $195.5M | $139.6M | $118.8M | $67.0M |
| Inventory | $759.3M | $659.2M | $848.1M | $299.0M | $237.0M | $229.2M | $196.3M | $131.3M | $108.4M | $112.7M |
| Total assets | $5.3B | $5.3B | $5.1B | $2.1B | $2.0B | $1.7B | $1.5B | $1.3B | $1.1B | $927.6M |
| Total liabilities | $729.5M | $1.1B | $1.1B | $229.8M | $215.9M | $173.2M | $129.6M | $115.2M | $110.7M | $95.6M |
| Shareholders' equity | $4.6B | $4.2B | $4.0B | $1.8B | $1.7B | $1.5B | $1.4B | $1.2B | $967.8M | $832.1M |
Growth · year-over-year · Revenue CAGR 20.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +16.7% | +60.6% | +53.3% | +6.8% | +21.4% | +0.5% | +10.2% | +12.1% | +12.8% | +3.5% |
| Net income growth | +422.3% | -16.2% | -35.4% | +27.5% | +45.9% | -34.1% | -0.8% | +45.8% | +2.9% | -7.5% |
| EPS growth | +422.7% | -29.9% | -42.2% | +28.5% | +42.6% | -33.6% | -1.3% | +40.0% | +1.9% | -7.7% |
| Free cash flow growth | +45.3% | +145.2% | +58.2% | -52.4% | +62.3% | +33.5% | -17.0% | +13.2% | +0.8% | +46.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.